Skip to main content Skip to search Skip to main navigation

PIC/S/EMA/WHO: New Q&A on Annex 1

The revision of Annex 1 also made it necessary to update the previous PIC/S interpretation document, PI 032-2, “GMP Annex 1 Revision 2008, Interpretation of Most Important Changes for the Manufacture of Sterile Medicinal Products”. Based on a Swissmedic draft from 2023, the joint PIC/S–EMA–WHO working group developed a new Q&A document. Following review by the participating organisations, it was adopted to ensure a consistent technical interpretation of Annex 1 across PIC/S, the EU and WHO.

The document explicitly states that it does not introduce new GMP requirements. In practice, however, it sharpens inspection expectations in many areas.

Some particularly relevant points include:

Contamination Control Strategy (CCS)
The effectiveness of the Contamination Control Strategy should be assessed continuously against the results obtained and reviewed at least annually. It does not have to be a single document, but should be structured and effectively managed. Existing systems may be referenced. A CCS may also be relevant to non-sterile products, for example where grade C/D cleanrooms are used.

VHP is not a sterilisation method
Vaporized hydrogen peroxide (VHP) is regarded only as a means of surface bio-decontamination. Where sterilisation is required, this is insufficient unless an equivalent level of sterility assurance can be demonstrated. The statement on lyophilisers is particularly clear: VHP bio-decontamination alone, in place of sterilisation, should be considered a deficiency.

PUPSIT
PUPSIT should be performed on filters used for final sterilising filtration wherever technically feasible. Manufacturers should consider any necessary design changes. An alternative approach requires process constraints that are not attributable to design flaws, together with a comprehensive risk assessment and appropriate risk mitigation measures.

A redundant filter that has not undergone PUPSIT cannot be used to support batch release if the primary filter fails the post-use integrity test. Risk assessments should not be used to inappropriately justify the omission of PUPSIT.

Single-Use Systems (SUS)
For critical SUS, an on-site audit of the manufacturer is normally expected, or evidence of the manufacturing site’s compliance. Reliance on supplier integrity testing requires in-depth supplier qualification. Supplier testing does not automatically replace the end-user’s own integrity testing: transport, installation and the complete assembly should be taken into account.

Aseptic Process Simulation (APS)
Initial validation should cover the entire maximum filling duration. Risk-based approaches may be used for subsequent APS runs, provided that the full duration is covered at defined intervals. The “frequency” of interventions generally refers to their absolute number. During annual personnel requalification, each operator should perform every type of intervention they are expected to carry out.

Even for validated isolators, the standard expectation remains at least two APS runs per year, for each aseptic process, filling line and shift. ISO 13408-1 does not override this expectation. Following a failed APS run, three consecutive repeat runs are normally required. Any reduction requires robust supporting data. If the APS programme has not been maintained during an extended shutdown, the initial APS validation is expected to be repeated before operations resume.


Source:

PIC/S: Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Medicinal Products (2022)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.
Read more
Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Previous
Next